These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38170429)

  • 21. Earliest radiological progression in glioblastoma by multidisciplinary consensus review.
    Eijgelaar RS; Bruynzeel AME; Lagerwaard FJ; Müller DMJ; Teunissen FR; Barkhof F; van Herk M; De Witt Hamer PC; Witte MG
    J Neurooncol; 2018 Sep; 139(3):591-598. PubMed ID: 29777418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
    Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
    Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroradiological response criteria for high-grade gliomas.
    Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
    Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparative Retrospective Study of Immunotherapy RANO
    Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
    Front Oncol; 2021; 11():679331. PubMed ID: 34249718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups.
    Karschnia P; Smits M; Reifenberger G; Le Rhun E; Ellingson BM; Galldiks N; Kim MM; Huse JT; Schnell O; Harter PN; Mohme M; ; von Baumgarten L; Albert NL; Huang RY; Mehta MP; van den Bent M; Weller M; Vogelbaum MA; Chang SM; Berger MS; Tonn JC
    Lancet Oncol; 2023 Nov; 24(11):e438-e450. PubMed ID: 37922934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
    Wen PY; Cloughesy TF; Ellingson BM; Reardon DA; Fine HA; Abrey L; Ballman K; Bendszuz M; Buckner J; Chang SM; Prados MD; Pope WB; Gregory Sorensen A; van den Bent M; Yung WK
    Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii36-47. PubMed ID: 25313237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging Criteria in Neuro-oncology.
    Nowosielski M; Wen PY
    Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
    van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
    Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
    Chinot OL; Macdonald DR; Abrey LE; Zahlmann G; Kerloëguen Y; Cloughesy TF
    Curr Neurol Neurosci Rep; 2013 May; 13(5):347. PubMed ID: 23529375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
    Albert NL; Galldiks N; Ellingson BM; van den Bent MJ; Chang SM; Cicone F; de Groot J; Koh ES; Law I; Le Rhun E; Mair MJ; Minniti G; Rudà R; Scott AM; Short SC; Smits M; Suchorska B; Tolboom N; Traub-Weidinger T; Tonn JC; Verger A; Weller M; Wen PY; Preusser M
    Lancet Oncol; 2024 Jan; 25(1):e29-e41. PubMed ID: 38181810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response Assessment in Neuro-Oncology Clinical Trials.
    Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
    J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current concepts in brain tumor imaging.
    Norden AD; Pope WB; Chang SM
    Am Soc Clin Oncol Educ Book; 2012; ():119-24. PubMed ID: 24451720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.
    Galanis E; Buckner JC; Maurer MJ; Sykora R; Castillo R; Ballman KV; Erickson BJ
    Neuro Oncol; 2006 Apr; 8(2):156-65. PubMed ID: 16533757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
    Hoff BA; Lemasson B; Chenevert TL; Luker GD; Tsien CI; Amouzandeh G; Johnson TD; Ross BD
    Acad Radiol; 2021 Dec; 28(12):1711-1720. PubMed ID: 32928633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Brain Tumor Response: RANO and Its Offspring.
    Eisele SC; Wen PY; Lee EQ
    Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
    de Godoy LL; Chawla S; Brem S; Mohan S
    Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudoprogression and pseudoresponse in the treatment of gliomas.
    Brandsma D; van den Bent MJ
    Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
    van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
    J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.